Omada Health, Inc. (OMDA)
AI stock analysis · as of Aug 10, 2026
Loading microstructure…
Omada Health (OMDA) is a recently-IPO'd (June 2025) virtual chronic care platform delivering programs for prediabetes, diabetes, hypertension, MSK, behavioral health, and GLP-1 companion care to ~886,000 enrolled members via employers, health plans, and PBMs. Revenue grew 53% YoY to $260M in FY2025 with gross margins near 66% and the company just reached a Q2 2026 profit inflection, sending shares up ~14% on the print. The core investment question is whether Omada can sustain 30%+ growth and expand its nascent profitability enough to justify a ~5.5x P/S and 45x forward P/E, while managing GLP-1 dependency, channel-partner concentration, and competition from Teladoc/Livongo and Hinge Health.
valuationExpensive on absolute multiples (45x fwd P/E, 5.5x P/S, 226x EV/EBITDA) but defensible given 53% revenue growth and just-achieved profit inflection; near 52-week highs with limited margin for error.
This analysis is from Aug 10, 2026. Want the latest on OMDA, plus the ability to generate fresh research on demand?
Every call we make is tracked publicly against what the stock actually did. See the track record →
One free AI report every day. No card required.
Bull case
- · Explosive top-line growth: revenue accelerated from $123M (2023) to $170M (2024) to $260M (2025), a 53% YoY print, while net losses narrowed sharply from -$67M to -$13M — operating leverage is emerging.
- · Profit inflection confirmed: Q2 2026 beat drove a ~19% single-day surge and $12.4M in positive free cash flow trailing, transitioning the story from cash-burn SaaS to self-funding growth.
- · GLP-1 tailwind + Eli Lilly partnership halo: 150,000+ members have used GLP-1s on platform, and new AOM prescribing capability layers new revenue on top of the fastest-growing obesity drug wave.
- · Sticky recurring revenue: 90%+ three-year customer retention and >55% member engagement at month 12 support durable ARR from 2,000+ customers.
- · Fortress balance sheet post-IPO: $222M cash, zero net debt after revolver repaid July 2025 — plenty of runway to invest without dilution risk.
- · Elevated short interest (13.7% of float, 6.7 days to cover) plus continued earnings momentum sets up potential squeeze dynamics on further beats.
Bear case
- · Valuation is demanding: 45x forward P/E, ~226x EV/EBITDA, and ~0.8% FCF yield leave essentially no margin for growth deceleration — the market is pricing perfection.
- · Customer concentration risk explicitly disclosed in the 10-K: two channel partners represent material portions of both revenue and A/R; loss of either would be catastrophic.
- · GLP-1 double-edged sword: if payers decide GLP-1 drugs replace rather than complement behavioral chronic-care programs, Omada's core cardiometabolic revenue could compress.
- · Competitive intensity: well-capitalized incumbents (Teladoc/Livongo, Hinge Health) and AI-native entrants threaten to commoditize point solutions and pressure pricing/CAC.
- · Profitability is razor-thin (1.4% profit margin, 4% operating margin, 1.8% ROE) — a modest customer loss, marketing ramp, or regulatory cost could flip the P&L back to losses.
- · Regulatory overhang: new AOM prescribing exposes the company to AKS/Stark/FCA scrutiny and state licensing complexity; FDA software-as-device reclassification is a tail risk.
- · 47 insider transactions in 180 days (though net-neutral in dollar terms) with only 2.2% insider ownership suggests limited skin-in-the-game post-lockup expiration.
Catalysts
- · Next earnings on November 5, 2026 — a second consecutive profitable quarter would validate the inflection thesis and drive further multiple expansion.
- · Short squeeze potential: 13.7% short float with 6.7 days to cover creates asymmetric upside on further beats or positive GLP-1 partnership news.
- · Q1-Q2 employer open-enrollment cycle prints showing continued covered-lives growth and cross-sell of multi-condition programs.
- · Expansion of the Eli Lilly / GLP-1 companion narrative, including additional pharma partnerships or new AOM prescribing traction.
- · New program launches (cholesterol, expanded behavioral health) driving ARPU expansion within existing 2,000+ customer base.
- · Analyst target upgrades post-Q2 beat — street target of $25.67 could be revised higher if next quarter confirms trajectory.
Key risks
- · Loss or renegotiation of one of the two concentrated channel partners disclosed in the 10-K.
- · GLP-1 payer dynamics shift against companion care programs, cratering the fastest-growing revenue vector.
- · Multiple compression from ~5.5x P/S if growth slows toward 25-30%, given comps trade materially lower.
- · Regulatory action on AOM prescribing, HIPAA breach, or FDA software reclassification.
- · Post-IPO lockup expirations increasing float and pressuring shares.
What to watch
- · November 5, 2026 earnings — margin trajectory, customer count, and any commentary on channel-partner concentration.
- · Short interest trend — currently 13.7% of float; a further build could set up a squeeze, a decline signals bears covering.
- · $26.91 52-week high as technical resistance; breakout on volume would confirm re-rating.
- · GLP-1/Eli Lilly partnership updates and AOM prescribing rollout metrics.
- · Any 8-K disclosures on customer wins/losses given the acknowledged two-partner concentration.
- · Post-IPO lockup expiration dates and insider Form 4 filings for direction of insider activity.
Key metrics
Price target rationale
Base case $26 applies ~6x forward sales on ~$340M FY26E revenue (30% growth off $260M), roughly in line with premium digital-health peers. Bull case $34 assumes sustained 40%+ growth, expanding margins toward 8-10%, and a squeeze on 13.7% short float. Bear case $15 reflects P/S compression to ~3x on growth deceleration, channel-partner loss, or GLP-1 disintermediation.
On Wall Street's view (mixed): The $25.67 street mean target (~8% upside from $23.67) looks reasonable as a base case but likely stale given the post-Q2 re-rating; the $15 low is too bearish for a company printing 53% growth with positive FCF, while the $30 high is achievable only if profit expansion continues linearly.
Latest filing (10-K)
Omada Health is a profitable-on-paper-someday virtual chronic care platform riding the GLP-1 wave with 886,000 enrolled members, 90%+ customer retention, and a freshly minted Nasdaq listing, but it remains unprofitable and dangerously concentrated in two channel partners.
Omada Health is a virtual chronic care company that delivers between-visit digital health programs for cardiometabolic conditions (diabetes prevention, diabetes management, hypertension, weight management, GLP-1 support) and musculoskeletal conditions. It sells to employers, health plans, and pharmacy benefit managers (B2B2C model), who cover program costs for their members. Revenue is generated through per-member fees billed via service contracts or electronic healthcare claims, with two revenue streams: services and hardware (connected devices shipped to members).
What the news says · bullish
The dominant storyline for OMDA is a strong Q2 2026 earnings beat that triggered a ~19% single-day surge and prompted analysts to raise price targets, with one 12-month target of $25.67 implying ~31% further upside. The company appears to have reached a profit inflection point, with headlines describing a 'record earnings' result and a 'profit turn' that is resetting the valuation debate. Broader momentum has been building since the IPO, with the stock reportedly up ~118% in three months as of mid-July, aided by its Eli Lilly partnership narrative. Options activity in $30 calls for early 2027 suggests some market participants are positioning for continued upside, though the put activity also indicates hedging. Coverage is reasonably substantive around the earnings catalyst, though several items are routine data/chart links that add little analytical weight.
This analysis is from Aug 10, 2026. Markets move. Get the current read on OMDA and generate fresh AI research on any ticker.
Every call we make is tracked publicly against what the stock actually did. See the track record →
One free AI report every day. No card required.